The role of AIB1 and PAX2 in breast cancer; validation of AIB1 as a prognostic factor in breast cancer

businessunknownInternet and Web Development

Nov 12, 2013 (3 years and 7 months ago)

293 views

Lista skapad 2012
-
11
-
26

2012


Alkner S
,
Bendahl PO
,
Malmström PO
,
Grabau D
,
Fernö

M
,
Rydén

L:
The

role of

AIB1

and PAX2

in

breast

cancer; validation

of AIB1

as a

prognostic

factor in

breast cancer
.
Accepted

for
Annals

of
Oncology

2012.

Allemani C, Sant M, Weir HK, Richardson LC, Baili P, Storm H, Siesling S, Torrella
-
Ramos A, Voogd AC,
Aareleid T, Ardanaz E, Berrino F, Bielska
-
Lasota M, Bolick S, Cirilli C, Colonna M, Contiero P,
Cress R, Crocetti E, Fulton JP, Grosclaude P, Hakulinen T,

Izarzugaza MI, Malmstrom P,
Peignaux K, Primic
-
Zakelj M, Rachtan J, Safaei Diba C, Sanchez MJ, Schymura MJ, Shen T,
Traina A, Tryggvadottir L, Tumino R, Velten M, Vercelli M, Wolf HJ, Woronoff AS, Wu X,
Coleman MP:
Breast cancer survival in the US and Eur
ope: A CONCORD high
-
resolution
study
.
International journal of cancer Journal international du cancer
2012.

Andersson Y, de Boniface J, Jonsson PE, Ingvar C, Liljegren G, Bergkvist L, Frisell J:
Axillary recurrence
rate 5 years after negative sentinel node

biopsy for breast cancer
.
The British journal of
surgery
2012,
99
(2):226
-
231.

Andersson Y, Frisell J, de Boniface J, Bergkvist L:
Prediction of non
-
sentinel lymph node status in
breast cancer patients with sentinel lymph node metastases: evaluation of the

tenon score
.
Breast cancer : basic and clinical research
2012,
6
:31
-
38.

Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, de Azambuja E, Aura C, Gomez H, Dinh P, Fauria K,
Van Dooren V, Aktan G, Goldhirsch A, Chang TW, Horvath Z, Coccia
-
Portugal M, Domont J
,
Tseng LM, Kunz G, Sohn JH, Semiglazov V, Lerzo G, Palacova M, Probachai V, Pusztai L, Untch
M, Gelber RD, Piccart
-
Gebhart M:
Lapatinib with trastuzumab for HER2
-
positive early breast
cancer (NeoALTTO): a randomised, open
-
label, multicentre, phase 3 trial
.
Lancet
2012,
379
(9816):633
-
640.

Bergh J, Bondarenko IM, Lichinitser MR, Liljegren A, Greil R, Voytko NL, Makhson AN, Cortes J,
Lortholary A, Bischoff J, Chan A, Delaloge S, Huang X, Kern KA, Giorgetti C:
First
-
line
treatment of advanced breast cancer wit
h sunitinib in combination with docetaxel versus
docetaxel alone: results of a prospective, randomized phase III study
.
J Clin Oncol
2012,
30
(9):921
-
929.

Bergh J, Jonsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattstrom D, Lindemann JP, Wiklund F,
Henrik
sson R:
FACT: an open
-
label randomized phase III study of fulvestrant and
anastrozole in combination compared with anastrozole alone as first
-
line therapy for
patients with receptor
-
positive postmenopausal breast cancer
.
J Clin Oncol
2012,
30
(16):1919
-
1925
.

Bergh J, Mariani G, Cardoso F, Liljegren A, Awada A, Vigano L, Huang X, Verkh L, Kern KA, Giorgetti C,
Gianni L:
Clinical and pharmacokinetic study of sunitinib and docetaxel in women with
advanced breast cancer
.
Breast
2012,
21
(4):507
-
513.

Berglund A, Wigertz A, Adolfsson J, Ahlgren J, Fornander T, Warnberg F, Lambe M:
Impact of
comorbidity on management and mortality in women diagnosed with breast cancer
.
Breast
cancer research and treatment
2012,
135
(1):281
-
289.

Bjorneklett HG, Lindemalm C
, Rosenblad A, Ojutkangas ML, Letocha H, Strang P, Bergkvist L:
A
randomised controlled trial of support group intervention after breast cancer treatment:
results on anxiety and depression
.
Acta oncologica
2012,
51
(2):198
-
207.

Brennan DJ, O'Connor DP, Laur
sen H, McGee SF, McCarthy S, Zagozdzon R, Rexhepaj E, Culhane AC,
Martin FM, Duffy MJ, Landberg G, Ryden L, Hewitt SM, Kuhar MJ, Bernards R, Millikan RC,
Crown JP, Jirstrom K, Gallagher WM:
The cocaine
-

and amphetamine
-
regulated transcript
mediates ligand
-
independent activation of ERalpha, and is an independent prognostic
factor in node
-
negative breast cancer
.
Oncogene
2012,
31
(30):3483
-
3494.

Busch S, Ryden L, Stal O, Jirstrom K, Landberg G:
Low ERK Phosphorylation in Cancer
-
Associated
Fibroblasts Is Associ
ated with Tamoxifen Resistance in Pre
-
Menopausal Breast Cancer
.
PLoS
One
2012,
7
(9):e45669.

Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin
N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Le
o A, El Saghir N, Ganz PA, Gelmon
K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M,
Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I, Winer E:
1st
International consensus guidelines for advanced breast
cancer (ABC 1)
.
Breast
2012,
21
(3):242
-
252.

Chirgwin J, Sun Z, Smith I, Price KN, Thurlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A,
Coates AS:
The advantage of letrozole over tamoxifen in the BIG 1
-
98 trial is consistent in
younger postmenopau
sal women and in those with chemotherapy
-
induced menopause
.
Breast cancer research and treatment
2012,
131
(1):295
-
306.

Eiermann W, Bergh J, Cardoso F, Conte P, Crown J, Curtin NJ, Gligorov J, Gusterson B, Joensuu H,
Linderholm BK, Martin M, Penault
-
Llorca
F, Pestalozzi BC, Razis E, Sotiriou C, Tjulandin S,
Viale G:
Triple negative breast cancer: proposals for a pragmatic definition and implications
for patient management and trial design
.
Breast
2012,
21
(1):20
-
26.

Eriksson L, Hall P, Czene K, Dos Santos Sil
va I, McCormack V, Bergh J, Bjohle J, Ploner A:
Mammographic density and molecular subtypes of breast cancer
.
British journal of cancer
2012,
107
(1):18
-
23.

Eschrich SA, Fulp WJ, Pawitan Y, Foekens JA, Smid M, Martens JW, Echevarria M, Kamath V, Lee JH,
Har
ris EE, Bergh J, Torres
-
Roca JF:
Validation of a radiosensitivity molecular signature in
breast cancer
.
Clinical cancer research : an official journal of the American Association for
Cancer Research
2012,
18
(18):5134
-
5143.

Falck AK, Bendahl PO, Ingvar C, I
sola J, Jonsson PE, Lindblom P, Lovgren K, Rennstam K, Ferno M,
Ryden L:
Analysis of and prognostic information from disseminated tumour cells in bone
marrow in primary breast cancer: a prospective observational study
.
BMC Cancer
2012,
12
:403.

Harris HR, Bergkvist L, Wolk A:
Alcohol intake and mortality among women with invasive breast
cancer
.
British journal of cancer
2012,
106
(3):592
-
595.

Harris HR, Bergkvist L, Wolk A:
Coffee and black tea consumption and breast cancer mortality in a
cohort o
f Swedish women
.
British journal of cancer
2012,
107
(5):874
-
878.

Harris HR, Bergkvist L, Wolk A:
Folate intake and breast cancer mortality in a cohort of Swedish
women
.
Breast cancer research and treatment
2012,
132
(1):243
-
250.

Harris HR, Bergkvist L, Wolk A:
Selenium intake and breast cancer mortality in a cohort of Swedish
women
.
Breast cancer research and treatment
2012,
134
(3):1269
-
1277.

Hatschek T, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Lindh B, Loman N, Malmberg
M, Rotstein
S, Soderberg M, Sundquist M, Walz TM, Hellstrom M, Svensson H, Astrom G, Brandberg Y,
Carstensen J, Ferno M, Bergh J:
Individually tailored treatment with epirubicin and
paclitaxel with or without capecitabine as first
-
line chemotherapy in meta
static breast
cancer: a randomized multicenter trial
.
Breast cancer research and treatment
2012,
131
(3):939
-
947.

Holm K, Grabau D, Lovgren K, Aradottir S, Gruvberger
-
Saal S, Howlin J, Saal LH, Ethier SP, Bendahl PO,
Stal O, Malmstrom P, Ferno M, Ryden L, H
egardt C, Borg A, Ringner M:
Global H3K27
trimethylation and EZH2 abundance in breast tumor subtypes
.
Mol Oncol
2012,
6
(5):494
-
506.

Hoyer M, Nordin K, Ahlgren J, Bergkvist L, Lambe M, Johansson B, Lampic C:
Change in working time
in a population
-
based coho
rt of patients with breast cancer
.
J Clin Oncol
2012,
30
(23):2853
-
2860.

Jonsson B, Bergh J:
Hurdles in anticancer drug development from a regulatory perspective
.
Nat Rev
Clin Oncol
2012,
9
(4):236
-
243.

Jonsson G, Staaf J, Vallon
-
Christersson J, Ringner M, G
ruvberger
-
Saal SK, Saal LH, Holm K, Hegardt C,
Arason A, Fagerholm R, Persson C, Grabau D, Johnsson E, Lovgren K, Magnusson L, Heikkila P,
Agnarsson BA, Johannsson OT, Malmstrom P, Ferno M, Olsson H, Loman N, Nevanlinna H,
Barkardottir RB, Borg A:
The reti
noblastoma gene undergoes rearrangements in BRCA1
-
deficient basal
-
like breast cancer
.
Cancer research
2012,
72
(16):4028
-
4036.

Julin B, Wolk A, Bergkvist L, Bottai M, Akesson A:
Dietary cadmium exposure and risk of
postmenopausal breast cancer: a
population
-
based prospective cohort study
.
Cancer
research
2012,
72
(6):1459
-
1466.

Lindemalm C, Granstam
-
Bjorneklett H, Bergkvist L, Ojutkangas ML, Strang P:
Existential aspects are
neglected in the evaluation of support
-
intervention in breast cancer patien
ts
.
Acta
oncologica
2012,
51
(6):807
-
809.

Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L,
Bergh J:
Clinically used breast cancer markers such as estrogen receptor, progesterone
receptor, and human epidermal gr
owth factor receptor 2 are unstable throughout tumor
progression
.
J Clin Oncol
2012,
30
(21):2601
-
2608.

Lundstedt D, Gustafsson M, Steineck G, Malmstrom P, Alsadius D, Sundberg A, Wilderang U,
Holmberg E, Johansson KA, Karlsson P:
Risk factors of developing

long
-
lasting breast pain
after breast cancer radiotherapy
.
International journal of radiation oncology, biology,
physics
2012,
83
(1):71
-
78.

Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ:
Carpal tunnel syndrome and
musculoskeletal symptoms in
postmenopausal women with early breast cancer treated
with exemestane or tamoxifen after 2
-
3 years of tamoxifen: a retrospective analysis of the
Intergroup Exemestane Study
.
The lancet oncology
2012,
13
(4):420
-
432.

Nagalingam A, Tighiouart M, Ryden L, Jose
ph L, Landberg G, Saxena NK, Sharma D:
Med1 plays a
critical role in the development of tamoxifen resistance
.
Carcinogenesis
2012,
33
(4):918
-
930.

Nilsson C, Johansson I, Ahlin C, Thorstenson S, Amini RM, Holmqvist M, Bergkvist L, Hedenfalk I,
Fjallskog ML:

Molecular subtyping of male breast cancer using alternative definitions and
its prognostic impact
.
Acta oncologica
2012.

Nilsson C, Koliadi A, Johansson I, Ahlin C, Thorstenson S, Bergkvist L, Hedenfalk I, Fjallskog ML:
High
proliferation is associated wi
th inferior outcome in male breast cancer patients
.
Mod
Pathol
2012.

Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, Wang
YC, Bergh J, Di Leo A, Albain K, Swain S, Piccart M, Pritchard K:
Comparisons between
dif
ferent polychemotherapy regimens for early breast cancer: meta
-
analyses of long
-
term
outcome among 100,000 women in 123 randomised trials
.
Lancet
2012,
379
(9814):432
-
444.

Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen

TO, Ellis MJ,
Carey LA, Perou CM:
Concordance among gene expression
-
based predictors for ER
-
positive
breast cancer treated with adjuvant tamoxifen
.
Annals of oncology : official journal of the
European Society for Medical Oncology / ESMO
2012,
23
(11):2866
-
2873.

Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thurlimann B, Cardoso F, Pagani O, Coates AS,
Goldhirsch A, Price KN, Gelber RD, Bernhard J:
Subjective cognitive complaints one year
after ceasing adjuvant endocrine treatment for earl
y
-
stage breast cancer
.
British journal of
cancer
2012,
106
(10):1618
-
1625.

Rosin G, Hannelius U, Lindstrom L, Hall P, Bergh J, Hartman J, Kere J:
The dyslexia candidate gene
DYX1C1 is a potential marker of poor survival in breast cancer
.
BMC Cancer
2012,
12
:79.

Sandberg ME, Alkner S, Hartman M, Eloranta S, Ryden L, Ploner A, Adami HO, Hall P, Czene K:
Influence of radiotherapy for the first tumor on aggressiveness of contralateral breast
cancer
.
International journal of cancer Journal international du cancer

2012.

Vichapat V, Garmo H, Holmqvist M, Liljegren G, Warnberg F, Lambe M, Fornander T, Adolfsson J,
Luchtenborg M, Holmberg L:
Tumor stage affects risk and prognosis of contralateral breast
cancer: results from a large Swedish
-
population
-
based study
.
J Cl
in Oncol
2012,
30
(28):3478
-
3485.

Welsh AW, Lannin DR, Young GS, Sherman ME, Figueroa JD, Henry NL, Ryden L, Kim C, Love RR, Schiff
R, Rimm DL:
Cytoplasmic estrogen receptor in breast cancer
.
Clinical cancer research : an
official journal of the American As
sociation for Cancer Research
2012,
18
(1):118
-
126.

Wigertz A, Ahlgren J, Holmqvist M, Fornander T, Adolfsson J, Lindman H, Bergkvist L, Lambe M:
Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a
population
-
based study
.

Breast cancer research and treatment
2012,
133
(1):367
-
373.


2011

Alkner S, Bendahl PO, Ferno M, Manjer J, Ryden L:
Prediction of outcome after diagnosis of
metachronous contralateral breast cancer
.
BMC Cancer
2011,
11
:114.

Andersson M, Lidbrink E, Bjerre
K, Wist E, Enevoldsen K, Jensen AB, Karlsson P, Tange UB, Sorensen
PG, Moller S

et al
:
Phase III randomized study comparing docetaxel plus trastuzumab with
vinorelbine plus trastuzumab as first
-
line therapy of metastatic or locally advanced human
epidermal

growth factor receptor 2
-
positive breast cancer: the HERNATA study
.
J Clin Oncol
2011,
29
(3):264
-
271.

Arver B, Isaksson K, Atterhem H, Baan A, Bergkvist L, Brandberg Y, Ehrencrona H, Emanuelsson M,
Hellborg H, Henriksson K, Karlsson P, Loman N, Lundberg J
, Ringberg A, Askmalm MS,
Wickman M, Sandelin K:
Bilateral prophylactic mastectomy in Swedish women at high risk
of breast cancer: a national survey
.
Annals of surgery
2011,
253
(6):1147
-
1154.

Berry DA, Ueno NT, Johnson MM, Lei X, Caputo J, Rodenhuis S, Pet
ers WP, Leonard RC, Barlow WE,
Tallman MS, Bergh J, Nitz UA, Gianni AM, Basser RL, Zander AR, Coombes RC, Roche H,
Tokuda Y, de Vries EG, Hortobagyi GN, Crown JP, Pedrazzoli P, Bregni M, Demirer T:
High
-
dose chemotherapy with autologous stem
-
cell support a
s adjuvant therapy in breast
cancer: overview of 15 randomized trials
.
J Clin Oncol
2011,
29
(24):3214
-
3223.

Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E

et al
:
TP53 status for prediction of sensiti
vity to taxane versus non
-
taxane neoadjuvant
chemotherapy in breast cancer (EORTC 10994/BIG 1
-
00): a randomised phase 3 trial
.
Lancet
Oncol
2011,
12
(6):527
-
539.

Brennan DJ, Laursen H, O'Connor DP, Borgquist S, Uhlen M, Gallagher WM, Ponten F, Millikan RC,
Ryden L, Jirstrom K:
Tumor
-
specific HMG
-
CoA reductase expression in primary
premenopausal breast cancer predicts response to tamoxifen
.
Breast Cancer Res
2011,
13
(1):R12.

Campa D, Claus R, Dostal L, Stein A, Chang
-
Claude J, Meidtner K, Boeing H, Olsen A,
Tjonneland A,
Overvad K

et al
:
Variation in genes coding for AMP
-
activated protein kinase (AMPK) and
breast cancer risk in the European Prospective Investigation on Cancer (EPIC)
.
Breast Cancer
Res Treat
2011.

Coleman MP, Forman D, Bryant H, Butler J, Rach
et B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J

et al
:
Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995
-
2007 (the International Cancer Benchmarking Partnership): an analysis of population
-
based
cancer registry data
.
Lanc
et
2011,
377
(9760):127
-
138.

Cserni G, Amendoeira I, Bianchi S, Chmielik E, Degaetano J, Faverly D, Figueiredo P, Foschini MP,
Grabau D, Jacquemier J

et al
:
Distinction of isolated tumour cells and micrometastasis in
lymph nodes of breast cancer patients ac
cording to the new Tumour Node Metastasis
(TNM) definitions
.
Eur J Cancer
2011,
47
(6):887
-
894.

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J,
Gray R, Pierce L, Whelan T, Wang Y, Peto R:
Effect of radio
therapy after breast
-
conserving
surgery on 10
-
year recurrence and 15
-
year breast cancer death: meta
-
analysis of individual
patient data for 10,801 women in 17 randomised trials
.
Lancet
2011,
378
(9804):1707
-
1716.

Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC,
Dowsett M, Ingle J, Peto R:
Relevance of breast cancer hormone receptors and other factors
to the efficacy of adjuvant tamoxifen: patient
-
level meta
-
analysis of r
andomised trials
.
Lancet
2011,
378
(9793):771
-
784.

Eaker S, Wigertz A, Lambert PC, Bergkvist L, Ahlgren J, Lambe M:
Breast cancer, sickness absence,
income and marital status. A study on life situation 1 year prior diagnosis compared to 3
and 5 years after
diagnosis
.
PLoS One
2011,
6
(3):e18040.

Edlund P, Ahlgren J, Bjerre K, Andersson M, Bergh J, Mouridsen H, Holmberg SB, Bengtsson NO,
Jakobsen E, Moller S

et al
:
Dose
-
tailoring of FEC adjuvant chemotherapy based on
leukopenia is feasible and well tolerated.
Toxicity and dose intensity in the Scandinavian
Breast Group phase 3 adjuvant Trial SBG 2000
-
1
.
Acta Oncol
2011,
50
(3):329
-
337.

Foukakis T, Fornander T, Lekberg T, Hellborg H, Adolfsson J, Bergh J:
Age
-
specific trends of survival in
metastatic breast cance
r: 26 years longitudinal data from a population
-
based cancer
registry in Stockholm, Sweden
.
Breast cancer research and treatment
2011,
130
(2):553
-
560.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ:
Strategies for subtypes
--
dealing with

the diversity of breast cancer: highlights of the St Gallen International Expert
Consensus on the Primary Therapy of Early Breast Cancer 2011
.
Ann Oncol
2011,
22
(8):1736
-
1747.

Hietala M, Henningson M, Ingvar C, Jonsson PE, Rose C, Jernstrom H:
Natural rem
edy use in a
prospective cohort of breast cancer patients in southern Sweden
.
Acta Oncol
2011,
50
(1):134
-
143.

Hillmer AM, Yao F, Inaki K, Lee WH, Ariyaratne PN, Teo AS, Woo XY, Zhang Z, Zhao H, Ukil L, Chen JP,
Zhu F, So JB, Salto
-
Tellez M, Poh WT, Zawack
KF, Nagarajan N, Gao S, Li G, Kumar V, Lim HP,
Sia YY, Chan CS, Leong ST, Neo SC, Choi PS, Thoreau H, Tan PB, Shahab A, Ruan X, Bergh J,
Hall P, Cacheux
-
Rataboul V, Wei CL, Yeoh KG, Sung WK, Bourque G, Liu ET, Ruan Y:
Comprehensive long
-
span paired
-
end
-
tag

mapping reveals characteristic patterns of
structural variations in epithelial cancer genomes
.
Genome Res
2011,
21
(5):665
-
675.

Hoyer M, Johansson B, Nordin K, Bergkvist L, Ahlgren J, Lidin
-
Lindqvist A, Lambe M, Lampic C:
Health
-
related quality of life
among women with breast cancer
-

a population
-
based study
.
Acta
oncologica
2011,
50
(7):1015
-
1026.

Iiristo M, Wiklund T, Wilking N, Bergh J, Brandberg Y:
Tailored chemotherapy doses based on
toxicity in breast cancer result in similar quality of life values
, irrespective of given dose
levels
.
Acta oncologica
2011,
50
(3):338
-
343.

Inaki K, Hillmer AM, Ukil L, Yao F, Woo XY, Vardy LA, Zawack KF, Lee CW, Ariyaratne PN, Chan YS,
Desai KV, Bergh J, Hall P, Putti TC, Ong WL, Shahab A, Cacheux
-
Rataboul V, Karuturi R
K, Sung
WK, Ruan X, Bourque G, Ruan Y, Liu ET:
Transcriptional consequences of genomic structural
aberrations in breast cancer
.
Genome Res
2011,
21
(5):676
-
687.

Isern AE, Manjer J, Malina J, Loman N, Martensson T, Bofin A, Hagen AI, Tengrup I, Landberg G,
R
ingberg A:
Risk of recurrence following delayed large flap reconstruction after
mastectomy for breast cancer
.
Br J Surg
2011.

Jerusalem G, Fasolo A, Dieras V, Cardoso F, Bergh J, Vittori L, Zhang Y, Massacesi C, Sahmoud T,
Gianni L:
Phase I trial of oral
mTOR inhibitor everolimus in combination with trastuzumab
and vinorelbine in pre
-
treated patients with HER2
-
overexpressing metastatic breast
cancer
.
Breast cancer research and treatment
2011,
125
(2):447
-
455.

Khoshnoud MR, Lofdahl B, Fohlin H, Fornander T,
Stal O, Skoog L, Bergh J, Nordenskjold B:
Immunohistochemistry compared to cytosol assays for determination of estrogen receptor
and prediction of the long
-
term effect of adjuvant tamoxifen
.
Breast cancer research and
treatment
2011,
126
(2):421
-
430.

Lehn S
, Ferno M, Jirstrom K, Ryden L, Landberg G:
A non
-
functional retinoblastoma tumor
suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to
tamoxifen
.
Cell Cycle
2011,
10
(6):956
-
962.

Lundgren K, Tobin NP, Lehn S, Stal O, Ryden

L, Jirstrom K, Landberg G:
Stromal expression of beta
-
arrestin
-
1 predicts clinical outcome and tamoxifen response in breast cancer
.
J Mol Diagn
2011,
13
(3):340
-
351.

Margolin S, Bengtsson NO, Carlsson L, Edlund P, Hellstrom M, Karlsson P, Lidbrink E, Linde
rholm B,
Lindman H, Malmstrom P

et al
:
A randomised feasibility/phase II study (SBG 2004
-
1) with
dose
-
dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed
dosed dose
-
dense EC/T versus T, doxorubicin and C (TAC) in
node
-
positive breast cancer
.
Acta Oncol
2011,
50
(1):35
-
41.

Miller LD, Coffman LG, Chou JW, Black MA, Bergh J, D'Agostino R, Jr., Torti SV, Torti FM:
An iron
regulatory gene signature predicts outcome in breast cancer
.
Cancer research
2011,
71
(21):6728
-
6737
.

Nilsson C, Holmqvist M, Bergkvist L, Hedenfalk I, Lambe M, Fjallskog ML:
Similarities and differences
in the characteristics and primary treatment of breast cancer in men and women
-

a
population based study (Sweden)
.
Acta oncologica
2011,
50
(7):1083
-
108
8.

Norenstedt S, Granath F, Ekbom A, Bergh J, Lambe M, Adolfsson J, Warnberg F, Zedenius J, Nilsson IL:
Breast cancer associated with primary hyperparathyroidism: a nested case control study
.
Clin Epidemiol
2011,
3
:103
-
106.

Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger
-
Saal S, Ringner M, Vallon
-
Christersson J,
Jonsson G, Holm K, Lovgren K, Ferno M, Grabau D, Borg A, Hegardt C:
CD44 isoforms are
heterogeneously expressed in breast cancer and correlate with tumor subtypes

and cancer
stem cell markers
.
BMC Cancer
2011,
11
:418.

Regan MM, Neven P, Giobbie
-
Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Lang
I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thurlimann B:
Assessment of
letrozole and
tamoxifen alone and in sequence for postmenopausal women with steroid
hormone receptor
-
positive breast cancer: the BIG 1
-
98 randomised clinical trial at 8.1 years
median follow
-
up
.
The lancet oncology
2011,
12
(12):1101
-
1108.

Regan MM, Price KN, Giobbie
-
Hur
der A, Thurlimann B, Gelber RD:
Interpreting Breast International
Group (BIG) 1
-
98: a randomized, double
-
blind, phase III trial comparing letrozole and
tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone
receptor
-
positive, early b
reast cancer
.
Breast Cancer Res
2011,
13
(3):209.

Rosell J, Nordenskjold B, Bengtsson NO, Fornander T, Hatschek T, Lindman H, Malmstrom PO,
Wallgren A, Stal O, Carstensen J:
Time dependent effects of adjuvant tamoxifen therapy on
cerebrovascular disease: re
sults from a randomised trial
.
British journal of cancer
2011,
104
(6):899
-
902.

Strand C, Ahlin C, Bendahl PO, Fjallskog ML, Hedenfalk I, Malmstrom P, Ferno M:
Combination of the
proliferation marker cyclin A, histological grade, and estrogen receptor statu
s in a new
variable with high prognostic impact in breast cancer
.
Breast Cancer Res Treat
2011.

Svensson H, Hatschek T, Johansson H, Einbeigi Z, Brandberg Y:
Health
-
related quality of life as
prognostic factor for response, progression
-
free survival, and
survival in women with
metastatic breast cancer
.
Med Oncol
2011.

Sverrisdottir A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist L, Fornander T:
Interaction
between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant
end
ocrine therapy in premenopausal breast cancer
.
Breast cancer research and treatment
2011,
128
(3):755
-
763.

Wennmalm K, Bergh J:
A simple method for assigning genomic grade to individual breast tumours
.
BMC Cancer
2011,
11
:306.

Wilking U, Karlsson E, Skoog L
, Hatschek T, Lidbrink E, Elmberger G, Johansson H, Lindstrom L, Bergh
J:
HER2 status in a population
-
derived breast cancer cohort: discordances during tumor
progression
.
Breast Cancer Res Treat
2011,
125
(2):553
-
561.


2010


Ahlin C, Ferno M, Amini RM, Tolockiene E, Blomqvist C, Bergh J, Fjallskog ML:
[Ki
-
67 and cyclin A
--
prognostic factors in breast cancer. Time to introduce proliferation markers in clinical
routine]
.
Lakartidningen
2010,
107
(10):672
-
675.

Alkner S, Bendahl PO
, Grabau D, Lovgren K, Stal O, Ryden L, Ferno M:
AIB1 is a predictive factor for
tamoxifen response in premenopausal women
.
Ann Oncol
2010,
21
(2):238
-
244.

Andersson Y, Frisell J, Sylvan M, de Boniface J, Bergkvist L:
Breast cancer survival in relation to t
he
metastatic tumor burden in axillary lymph nodes
.
J Clin Oncol
2010,
28
(17):2868
-
2873.

Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR,
Weitzel JN, Lynch HT

et al
:
Common breast cancer susceptibility
alleles and the risk of
breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction
.
Cancer Res
2010,
70
(23):9742
-
9754.

Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J,
Kartsonaki
C, Lesnick T

et al
:
A locus on 19p13 modifies risk of breast cancer in BRCA1
mutation carriers and is associated with hormone receptor
-
negative breast cancer in the
general population
.
Nat Genet
2010,
42
(10):885
-
892.

Correa C, McGale P, Taylor C, Wang Y, C
larke M, Davies C, Peto R, Bijker N, Solin L, Darby S:
Overview
of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast
.
J Natl
Cancer Inst Monogr
2010,
2010
(41):162
-
177.

Einbeigi Z, Enerback C, Wallgren A, Nordling M, Karlsson P
:
BRCA1 gene mutations may explain more
than 80% of excess number of ovarian cancer cases after breast cancer
-

a population
based study from the Western Sweden Health Care region
.
Acta Oncol
2010,
49
(3):361
-
367.

Engel C, Versmold B, Wappenschmidt B, Simar
d J, Easton DF, Peock S, Cook M, Oliver C, Frost D,
Mayes R

et al
:
Association of the variants CASP8 D302H and CASP10 V410I with breast and
ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
.
Cancer Epidemiol Biomarkers
Prev
2010,
19
(11):2859
-
2868.

Garcia
-
Caballero T, Grabau D, Green AR, Gregory J, Schad A, Kohlwes E, Ellis IO, Watts S, Mollerup J:
Determination of HER2 amplification in primary breast cancer using dual
-
colour
chromogenic in situ hybridization is comparable to fluorescence in situ hyb
ridization: a
European multicentre study involving 168 specimens
.
Histopathology
2010,
56
(4):472
-
480.

Howell A, Bergh J:
Insights Into the Place of Fulvestrant for the Treatment of Advanced Endocrine
Responsive Breast Cancer
.
Journal of Clinical Oncology
2
010,
28
(30):4548
-
4550.

Kallstrom AC, Salme R, Ryden L, Nordenskjold B, Jonsson PE, Stal O:
17ss
-
Hydroxysteroid
dehydrogenase type 1 as predictor of tamoxifen response in premenopausal breast cancer
.
Eur J Cancer
2010,
46
(5):892
-
900.

Khoshnoud R, He Q, Sylv
an M, Khoshnoud A, Ivarsson M, Fornander T, Bergh J, Frisell J, Rutqvist LE,
Skog S:
The impact of RNA standardization and heterogeneous gene expression on the
results of cDNA array of human breast carcinoma
.
Int J Mol Med
2010,
25
(5):735
-
741.

Klintman M,
Bendahl PO, Grabau D, Lovgren K, Malmstrom P, Ferno M:
The prognostic value of Ki67
is dependent on estrogen receptor status and histological grade in premenopausal patients
with node
-
negative breast cancer
.
Mod Pathol
2010,
23
(2):251
-
259.

Korde LA, Zujews
ki JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh
Z, Bergh J

et al
:
Multidisciplinary meeting on male breast cancer: summary and research
recommendations
.
J Clin Oncol
2010,
28
(12):2114
-
2122.

Lambe M, Wigertz A, Holmqvist M,

Adolfsson J, Bardage C, Fornander T, Karlsson P, Odlind V, Persson
I, Ahlgren J

et al
:
Reductions in use of hormone replacement therapy: effects on Swedish
breast cancer incidence trends only seen after several years
.
Breast Cancer Res Treat
2010,
121
(3):
679
-
683.

Lindström L, Howell S, Åström G, Wilking U, Lidbrink E, Armstrong A, Karlsson E, Hatschek T, Bergh J:
Controversies in the management of metastatic breast cancer: biologic evaluation of breast
cancer
-

Should metastases be biopsised?

ASCO Educatio
nal
2010.

Lundstedt D, Gustafsson M, Malmstrom P, Johansson KA, Alsadius D, Sundberg A, Wilderang U,
Holmberg E, Anderson H, Steineck G

et al
:
Symptoms 10
-
17 years after breast cancer
radiotherapy data from the randomised SWEBCG91
-
RT trial
.
Radiother Oncol
2010,
97
(2):281
-
287.

Malmstrom A, Hansen J, Malmberg L, Carlsson L, Svensson JH, Ahlgren J, Ahlin C, Jansson T, Westberg
R:
Gemcitabine and capecitabine in combination for advanced anthracycline and taxane
pre
-
treated breast cancer patients
: A phase II study
.
Acta Oncol
2010,
49
(1):35
-
41.

Ofverholm A, Arkblad E, Skrtic S, Albertsson P, Shubbar E, Enerback C:
Two cases of 5
-
fluorouracil
toxicity linked with gene variants in the DPYD gene
.
Clin Biochem
2010,
43
(3):331
-
334.

Paridaens RJ, Gelber

S, Cole BF, Gelber RD, Thurlimann B, Price KN, Holmberg SB, Crivellari D, Coates
AS, Goldhirsch A:
Adjuvant! Online estimation of chemotherapy effectiveness when added
to ovarian function suppression plus tamoxifen for premenopausal women with estrogen
-
re
ceptor
-
positive breast cancer
.
Breast Cancer Res Treat
2010,
123
(1):303
-
310.

Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Ryden L, Luts L, Bendahl PO, Hedenfalk
I:
Numb protein expression correlates with a basal
-
like phenotype and cancer stem
cell
markers in primary breast cancer
.
Breast Cancer Res Treat
2010,
122
(2):315
-
324.

Rennstam K, Ringberg A, Cunliffe HE, Olsson H, Landberg G, Hedenfalk I:
Genomic alterations in
histopathologically normal breast tissue from BRCA1 mutation carriers may be

caused by
BRCA1 haploinsufficiency
.
Genes Chromosomes Cancer
2010,
49
(1):78
-
90.

Ryden L, Grabau D, Schaffner F, Jonsson PE, Ruf W, Belting M:
Evidence for tissue factor
phosphorylation and its correlation with protease
-
activated receptor expression and th
e
prognosis of primary breast cancer
.
Int J Cancer
2010,
126
(10):2330
-
2340.

Ryden L, Jirstrom K, Haglund M, Stal O, Ferno M:
Epidermal growth factor receptor and vascular
endothelial growth factor receptor 2 are specific biomarkers in triple
-
negative breas
t
cancer. Results from a controlled randomized trial with long
-
term follow
-
up
.
Breast Cancer
Res Treat
2010,
120
(2):491
-
498.

Sackey H, Sandelin K, Frisell J, Wickman M, Brandberg Y:
Ductal carcinoma in situ of the breast.
Long
-
term follow
-
up of health
-
rela
ted quality of life, emotional reactions and body image
.
Eur J Surg Oncol
2010,
36
(8):756
-
762.

Staaf J, Jonsson G, Ringner M, Vallon
-
Christersson J, Grabau D, Arason A, Gunnarsson H, Agnarsson
BA, Malmstrom PO, Johannsson OT

et al
:
High
-
resolution genomic
and expression analyses
of copy number alterations in HER2
-
amplified breast cancer
.
Breast Cancer Res
2010,
12
(3):R25.

Staaf J, Ringner M, Vallon
-
Christersson J, Jonsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H,
Hegardt C, Agnarsson BA

et al
:
Identifi
cation of subtypes in human epidermal growth factor
receptor 2
--
positive breast cancer reveals a gene signature prognostic of outcome
.
J Clin
Oncol
2010,
28
(11):1813
-
1820.

Stendahl M, Nilsson S, Wigerup C, Jirstrom K, Jonsson PE, Stal O, Landberg G:
p27(Ki
p1) is a
predictive factor for tamoxifen treatment response but not a prognostic marker in
premenopausal breast cancer patients
.
Int J Cancer
2010,
127
(12):2851
-
2858.

Styring E, Fernebro J, Jonsson PE, Ehinger A, Engellau J, Rissler P, Rydholm A, Nilbert M
, Vult von
Steyern F:
Changing clinical presentation of angiosarcomas after breast cancer: from late
tumors in edematous arms to earlier tumors on the thoracic wall
.
Breast Cancer Res Treat
2010,
122
(3):883
-
887.

Svensson H, Einbeigi Z, Johansson H, Hatsche
k T, Brandberg Y:
Quality of life in women with
metastatic breast cancer during 9 months after randomization in the TEX trial (epirubicin
and paclitaxel w/o capecitabine)
.
Breast Cancer Res Treat
2010,
123
(3):785
-
793.

Tutt A, Robson M, Garber JE, Domchek
SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N,
Schmutzler RK

et al
:
Oral poly(ADP
-
ribose) polymerase inhibitor olaparib in patients with
BRCA1 or BRCA2 mutations and advanced breast cancer: a proof
-
of
-
concept trial
.
Lancet
2010,
376
(9737):235
-
24
4.

Wilking U, Jonsson B, Wilking N, Bergh J:
Trastuzumab use in breast cancer patients in the six Health
Care Regions in Sweden
.
Acta Oncol
2010,
49
(6):844
-
850.


2009


Alkner S, Bendahl PO, Ferno M, Nordenskjold B, Ryden L:
Tamoxifen reduces the risk of
contralateral
breast cancer in premenopausal women: Results from a controlled randomised trial
.
Eur J
Cancer
2009,
45
(14):2496
-
2502.

Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB,
Beesley J, Chen X

et al
:
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for
BRCA1 and BRCA2 mutation carriers
.
Hum Mol Genet
2009,
18
(22):4442
-
4456.

Bergh J:
Quo vadis with targeted drugs in the 21st century?

J Clin Oncol
2009,
27
(1):2
-
5.

Colleoni M, Sun Z, Martin
elli G, Basser RL, Coates AS, Gelber RD, Green MD, Peccatori F, Cinieri S,
Aebi S

et al
:
The effect of endocrine responsiveness on high
-
risk breast cancer treated with
dose
-
intensive chemotherapy: results of International Breast Cancer Study Group Trial 15
-
95 after prolonged follow
-
up
.
Ann Oncol
2009,
20
(8):1344
-
1351.

Eaker S, Halmin M, Bellocco R, Bergkvist L, Ahlgren J, Holmberg L, Lambe M:
Social differences in
breast cancer survival in relation to patient management within a National Health Care
System
(Sweden)
.
Int J Cancer
2009,
124
(1):180
-
187.

Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Becette V, Andre S, Piccart M, Campone M,
Brain E

et al
:
A stroma
-
related gene signature predicts resistance to neoadjuvant
chemotherapy in breast cancer
.
Nat Med
2009,
15
(1):68
-
74.

Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H:
Breast cancer in young women:
poor survival despite intensive treatment
.
PLoS One
2009,
4
(11):e7695.

Giobbie
-
Hurder A, Price KN, Gelber RD:
Design, conduct,
and analyses of Breast International Group
(BIG) 1
-
98: a randomized, double
-
blind, phase
-
III study comparing letrozole and tamoxifen
as adjuvant endocrine therapy for postmenopausal women with receptor
-
positive, early
breast cancer
.
Clin Trials
2009,
6
(3):
272
-
287.

Holmberg L, Duffy SW, Yen AM, Tabar L, Vitak B, Nystrom L, Frisell J:
Differences in endpoints
between the Swedish W
-
E (two county) trial of mammographic screening and the Swedish
overview: methodological consequences
.
J Med Screen
2009,
16
(2):73
-
80.

Jernstrom H, Bageman E, Rose C, Jonsson PE, Ingvar C:
CYP2C8 and CYP2C9 polymorphisms in
relation to tumour characteristics and early breast cancer related events among 652 breast
cancer patients
.
Br J Cancer
2009,
101
(11):1817
-
1823.

Joensuu H, Kelloku
mpu
-
Lehtinen PL, Huovinen R, Jukkola
-
Vuorinen A, Tanner M, Asola R, Kokko R,
Ahlgren J, Auvinen P, Hemminki A

et al
:
Adjuvant capecitabine in combination with
docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open
-
label,
randomised contr
olled trial
.
Lancet Oncol
2009,
10
(12):1145
-
1151.

Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, Chen X, Gschwantler
-
Kaulich D,
Singer CF, Fuerhauser C

et al
:
No evidence that GATA3 rs570613 SNP modifies breast cancer
risk
.
Breast

Cancer Res Treat
2009,
117
(2):371
-
379.

Kenne Sarenmalm E, Oden A, Ohlen J, Gaston
-
Johansson F, Holmberg SB:
Changes in health
-
related
quality of life may predict recurrent breast cancer
.
Eur J Oncol Nurs
2009,
13
(5):323
-
329.

Killander F, Anderson H, Ryden

S, Moller T, Hafstrom LO, Malmstrom P:
Efficient reduction of loco
-
regional recurrences but no effect on mortality twenty years after postmastectomy
radiation in premenopausal women with stage II breast cancer
-

a randomized trial from
the South Sweden Br
east Cancer Group
.
Breast
2009,
18
(5):309
-
315.

Koscielny S, Arriagada R, Adolfsson J, Fornander T, Bergh J:
Impact of tumour size on axillary
involvement and distant dissemination in breast cancer
.
Br J Cancer
2009,
101
(6):902
-
907.

Larsson AM, Jirstrom K,
Fredlund E, Nilsson S, Ryden L, Landberg G, Pahlman S:
Erythropoietin
receptor expression and correlation to tamoxifen response and prognosis in breast cancer
.
Clin Cancer Res
2009,
15
(17):5552
-
5559.

Mansson E, Bergkvist L, Christenson G, Persson C, Warnberg F:
Mammographic casting
-
type
calcifications is not a prognostic factor in unifocal small invasive breast cancer: a
population
-
based retrospective cohort study
.
J Surg Oncol
2009,
100
(8):670
-
674.

Mo
uridsen H, Giobbie
-
Hurder A, Goldhirsch A, Thurlimann B, Paridaens R, Smith I, Mauriac L, Forbes
JF, Price KN, Regan MM

et al
:
Letrozole therapy alone or in sequence with tamoxifen in
women with breast cancer
.
N Engl J Med
2009,
361
(8):766
-
776.

Osorio A, M
ilne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix
-
Trench G, Spurdle AB,
Beesley J, Chen X

et al
:
Evaluation of a candidate breast cancer associated SNP in ERCC4 as
a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consorti
um of
Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
.
Br J Cancer
2009,
101
(12):2048
-
2054.

Pagani O, Gelber S, Simoncini E, Castiglione
-
Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari
D, Collins J, Lindtner J

et al
:
Is adjuvant chemotherapy of b
enefit for postmenopausal
women who receive endocrine treatment for highly endocrine
-
responsive, node
-
positive
breast cancer? International Breast Cancer Study Group Trials VII and 12
-
93
.
Breast Cancer
Res Treat
2009,
116
(3):491
-
500.

Pagani O, Price KN, Ge
lber RD, Castiglione
-
Gertsch M, Holmberg SB, Lindtner J, Thurlimann B, Collins
J, Fey MF, Coates AS

et al
:
Patterns of recurrence of early breast cancer according to
estrogen receptor status: a therapeutic target for a quarter of a century
.
Breast Cancer R
es
Treat
2009,
117
(2):319
-
324.

Rabaglio M, Sun Z, Price KN, Castiglione
-
Gertsch M, Hawle H, Thurlimann B, Mouridsen H, Campone
M, Forbes JF, Paridaens RJ

et al
:
Bone fractures among postmenopausal patients with
endocrine
-
responsive early breast cancer trea
ted with 5 years of letrozole or tamoxifen in
the BIG 1
-
98 trial
.
Ann Oncol
2009,
20
(9):1489
-
1498.

Rosendahl M, Ahlgren J, Andersen J, Bergh J, Blomquist C, Lidbrink E, Lindman H, Mouridsen H, Bjerre
K, Andersson M:
The risk of amenorrhoea after adjuvant
chemotherapy for early stage
breast cancer is related to inter
-
individual variations in chemotherapy
-
induced leukocyte
nadir in young patients: data from the randomised SBG 2000
-
1 study
.
Eur J Cancer
2009,
45
(18):3198
-
3204.

Ryden L, Haglund M, Bendahl PO,
Hatschek T, Kolaric A, Kovacs A, Olsson A, Olsson H, Strand C, Ferno
M:
Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast
cancer: a national survey performed at pathology departments in Sweden
.
Acta Oncol
2009,
48
(6):860
-
866.

Thurlimann B, Price KN, Gelber RD, Holmberg SB, Crivellari D, Colleoni M, Collins J, Forbes JF,
Castiglione
-
Gertsch M, Coates AS

et al
:
Is chemotherapy necessary for premenopausal
women with lower
-
risk node
-
positive, endocrine responsive breas
t cancer? 10
-
year update
of International Breast Cancer Study Group Trial 11
-
93
.
Breast Cancer Res Treat
2009,
113
(1):137
-
144.


2008


Axelsson CK, Jonsson PE:
Sentinel lymph node biopsy in operations for recurrent breast cancer
.
Eur
J Surg Oncol
2008,
34
(6
):626
-
630.

Bergkvist L, de Boniface J, Jonsson PE, Ingvar C, Liljegren G, Frisell J:
Axillary recurrence rate after
negative sentinel node biopsy in breast cancer: three
-
year follow
-
up of the Swedish
Multicenter Cohort Study
.
Ann Surg
2008,
247
(1):150
-
156.

Berglund P, Stighall M, Jirstrom K, Ryden L, Ferno M, Nordenskjold B, Landberg G:
Cyclin E confers a
prognostic value in premenopausal breast cancer patients with tumours exhibiting an
infiltrative growth pattern
.
J Clin Pathol
2008,
61
(2):184
-
191.

Clarke

M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, Goldhirsch A, Gray R, Peto R, Pritchard
KI

et al
:
Adjuvant chemotherapy in oestrogen
-
receptor
-
poor breast cancer: patient
-
level
meta
-
analysis of randomised trials
.
Lancet
2008,
371
(9606):29
-
40.

Dihge
L, Bendahl PO, Grabau D, Isola J, Lovgren K, Ryden L, Ferno M:
Epidermal growth factor
receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for
predicting clinical outcome after adjuvant tamoxifen in breast cancer
.
Breast C
ancer Res
Treat
2008,
109
(2):255
-
262.

Einbeigi Z, Bergstrom D, Hatschek T, Malmberg M:
Paclitaxel, Epirubicin and Capecitabine (TEX) as
first
-
line treatmnet for metastatic breast cancer: a pilot phase I/II feasibility study
.
Clinical
Medicine Insights: Oncology
2008(2):533
-
538.

Ferno M, Haglund M, Bendahl PO, Olsson H, Ryden L:
[Quality assured HER2 analysis in breast
cancer. Important therapeutic predictive and prognostic factor]
.
Lakartidningen
2008,
105
(32
-
33):2181
-
2184.

Gi
anni L, Cole BF, Panzini I, Snyder R, Holmberg SB, Byrne M, Crivellari D, Colleoni M, Aebi S,
Simoncini E

et al
:
Anemia during adjuvant non
-
taxane chemotherapy for early breast
cancer: Incidence and risk factors from two trials of the International Breast
Cancer Study
Group
.
Support Care Cancer
2008,
16
(1):67
-
74.

Gruber G, Cole BF, Castiglione
-
Gertsch M, Holmberg SB, Lindtner J, Golouh R, Collins J, Crivellari D,
Thurlimann B, Simoncini E

et al
:
Extracapsular tumor spread and the risk of local, axillary
and

supraclavicular recurrence in node
-
positive, premenopausal patients with breast
cancer
.
Ann Oncol
2008,
19
(8):1393
-
1401.

Holmberg L, Garmo H, Granstrand B, Ringberg A, Arnesson LG, Sandelin K, Karlsson P, Anderson H,
Emdin S:
Absolute risk reductions for
local recurrence after postoperative radiotherapy
after sector resection for ductal carcinoma in situ of the breast
.
J Clin Oncol
2008,
26
(8):1247
-
1252.

Isern AE, Loman N, Malina J, Olsson H, Ringberg A:
Histopathological findings and follow
-
up after
proph
ylactic mastectomy and immediate breast reconstruction in 100 women from
families with hereditary breast cancer
.
Eur J Surg Oncol
2008,
34
(10):1148
-
1154.

Isern AE, Tengrup I, Loman N, Olsson H, Ringberg A:
Aesthetic outcome, patient satisfaction, and
healt
h
-
related quality of life in women at high risk undergoing prophylactic mastectomy
and immediate breast reconstruction
.
J Plast Reconstr Aesthet Surg
2008,
61
(10):1177
-
1187.

Jerevall PL, Brommesson S, Strand C, Gruvberger
-
Saal S, Malmstrom P, Nordenskjold
B, Wingren S,
Soderkvist P, Ferno M, Stal O:
Exploring the two
-
gene ratio in breast cancer
-

independent
roles for HOXB13 and IL17BR in prediction of clinical outcome
.
Breast Cancer Research and
Treatment
2008,
107
(2):225
-
234.

Kristensen B, Ejlertsen B, Mo
uridsen HT, Jensen MB, Andersen J, Bjerregaard B, Cold S, Edlund P,
Ewertz M, Kamby C

et al
:
Bisphosphonate treatment in primary breast cancer: results from
a randomised comparison of oral pamidronate versus no pamidronate in patients with
primary breast c
ancer
.
Acta Oncol
2008,
47
(4):740
-
746.

Linderholm BK, Gruvberger
-
Saal S, Ferno M, Bendahl PO, Malmstrom P:
Vascular endothelial growth
factor is a strong predictor of early distant recurrences in a prospective study of
premenopausal women with lymph
-
node
negative breast cancer
.
Breast
2008,
17
(5):484
-
491.

Nimeus
-
Malmstrom E, Krogh M, Malmstrom P, Strand C, Fredriksson I, Karlsson P, Nordenskjold B,
Stal O, Ostberg G, Peterson C

et al
:
Gene expression profiling in primary breast cancer
distinguishes patient
s developing local recurrence after breast
-
conservation surgery, with
or without postoperative radiotherapy
.
Breast Cancer Res
2008,
10
(2):R34.

Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J,
Snyder R, Thurli
mann B

et al
:
Distinct clinical and prognostic features of infiltrating lobular
carcinoma of the breast: combined results of 15 International Breast Cancer Study Group
clinical trials
.
J Clin Oncol
2008,
26
(18):3006
-
3014.

Ravaioli A, Monti F, Regan MM, Maf
fini F, Mastropasqua MG, Spataro V, Castiglione
-
Gertsch M,
Panzini I, Gianni L, Goldhirsch A

et al
:
p27 and Skp2 immunoreactivity and its clinical
significance with endocrine and chemo
-
endocrine treatments in node
-
negative early breast
cancer
.
Ann Oncol
20
08,
19
(4):660
-
668.

Regan MM, Pagani O, Walley B, Torrisi R, Perez EA, Francis P, Fleming GF, Price KN, Thurlimann B,
Maibach R

et al
:
Premenopausal endocrine
-
responsive early breast cancer: who receives
chemotherapy?

Ann Oncol
2008,
19
(7):1231
-
1241.

Ryden
L, Landberg G, Stal O, Nordenskjold B, Ferno M, Bendahl PO:
HER2 status in hormone
receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen
treatment predictive, information
.
Breast Cancer Res Treat
2008,
109
(2):351
-
357.

Sve
nsson H, Brandberg Y, Einbeigi Z, Hatschek T, Ahlberg K:
Psychological Reactions to Progression
of Metastatic Breast Cancer
-
An Interview Study
.
Cancer Nurs
2008.

Viale G, Giobbie
-
Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell'Orto P, Maiorano E,
MacGrogan G, Braye SG, Ohlschlegel C

et al
:
Prognostic and predictive value of centrally
reviewed Ki
-
67 labeling index in postmenopausal women with endocrine
-
responsive breast
cancer: results from Breast International Group Trial 1
-
98 comparing adjuvant ta
moxifen
with letrozole
.
J Clin Oncol
2008,
26
(34):5569
-
5575.


2007


Ahlqvist
-
Rastad J, Albertsson M, Bergh J, Birgegard G, Johansson P, Jonsson B, Kjellen E, Pahlman S,
Zackrisson B, Osterborg A:
Erythropoietin therapy and cancer related anaemia: updated
Swedish recommendations
.
Med Oncol
2007,
24
(3):267
-
272.

Celebioglu F, Frisell J, Danielsson R, Bergkvist L:
Sentinel node biopsy in non
-
palpable breast cancer
and in patients with a previous diagnostic excision
.
Eur J Surg Oncol
2007,
33
(3):276
-
280.

Celebi
oglu F, Perbeck L, Frisell J, Grondal E, Svensson L, Danielsson R:
Lymph drainage studied by
lymphoscintigraphy in the arms after sentinel node biopsy compared with axillary lymph
node dissection following conservative breast cancer surgery
.
Acta Radiol
20
07,
48
(5):488
-
495.

Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ,
Delozier T, Alvarez I

et al
:
Survival and safety of exemestane versus tamoxifen after 2
-
3
years' tamoxifen treatment (Intergroup Exemestane

Study): a randomised controlled trial
.
Lancet
2007,
369
(9561):559
-
570.

Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe
-
Kains B, Viale G, Delorenzi M, Zhang Y,
d'Assignies MS

et al
:
Strong time dependence of the 76
-
gene prognostic signature for node
-
negative breast cancer patients in the TRANSBIG multicenter independent validation
series
.
Clin Cancer Res
2007,
13
(11):3207
-
3214.

Einbeigi Z, Bergman A, Meis
-
Kindblom JM, Flodin A, Bjursell C, Martinsson T, Kindblom LG,
Wahlstrom J, Wallgren A, Nordling
M

et al
:
Occurrence of both breast and ovarian cancer in
a woman is a marker for the BRCA gene mutations: a population
-
based study from western
Sweden
.
Fam Cancer
2007,
6
(1):35
-
41.

Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Cold S, Edlund P, Ewertz
M, Jensen BB, Kamby C,
Nordenskjold B

et al
:
Improved outcome from substituting methotrexate with epirubicin:
results from a randomised comparison of CMF versus CEF in patients with primary breast
cancer
.
Eur J Cancer
2007,
43
(5):877
-
884.

Grabau D, Jensen MB, Rank F, Blichert
-
Toft M:
Axillary lymph node micrometastases in invasive
breast cancer: national figures on incidence and overall survival
.
APMIS
2007,
115
(7):828
-
837.

Hartman M, Czene K, Reilly M, Adolfsson J, Bergh J, Adami HO, Dickm
an PW, Hall P:
Incidence and
prognosis of synchronous and metachronous bilateral breast cancer
.
J Clin Oncol
2007,
25
(27):4210
-
4216.

Karlsson P, Cole BF, Price KN, Coates AS, Castiglione
-
Gertsch M, Gusterson BA, Murray E, Lindtner J,
Collins JP, Holmberg S
B

et al
:
The role of the number of uninvolved lymph nodes in
predicting locoregional recurrence in breast cancer
.
J Clin Oncol
2007,
25
(15):2019
-
2026.

Kellokumpu
-
Lehtinen P, Bergh J, Salminen E, Wiklund T, Lehtinen S, Aronen P, Sintonen H:
Cost
-
effectivene
ss of intensive adjuvant chemotherapy for high
-
risk breast cancer: is tailored
and dose
-
escalated chemotherapy with growth factor support (GFS) more costly and less
effective than marrow
-
supported high
-
dose chemotherapy
-

results from a randomized
study
.
A
cta Oncol
2007,
46
(2):146
-
152.

Killander F, Anderson H, Ryden S, Moller T, Aspegren K, Ceberg J, Danewid C, Malmstrom P:
Radiotherapy and tamoxifen after mastectomy in postmenopausal women
--

20 year
follow
-
up of the South Sweden Breast Cancer Group random
ised trial SSBCG II:I
.
Eur J
Cancer
2007,
43
(14):2100
-
2108.

Lindman H, Astrom G, Ahlgren J, Villman K, Blomqvist C, Nygren P, Bergh J:
Individually tailored
toxicity
-
based 5
-
fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic
breast c
ancer
.
Acta Oncol
2007,
46
(2):165
-
171.

Loi S, Haibe
-
Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA

et al
:
Definition of clinically distinct molecular subtypes in estrogen receptor
-
positive
breast carcinomas throu
gh genomic grade
.
J Clin Oncol
2007,
25
(10):1239
-
1246.

Lundkvist J, Wilking N, Holmberg S, Jonsson L:
Cost
-
effectiveness of exemestane versus tamoxifen as
adjuvant therapy for early
-
stage breast cancer after 2
-
3 years treatment with tamoxifen in
Sweden
.
Br
east Cancer Res Treat
2007,
102
(3):289
-
299.

Ringberg A, Nordgren H, Thorstensson S, Idvall I, Garmo H, Granstrand B, Arnesson LG, Sandelin K,
Wallgren A, Anderson H

et al
:
Histopathological risk factors for ipsilateral breast events
after breast conserving

treatment for ductal carcinoma in situ of the breast
--
results from
the Swedish randomised trial
.
Eur J Cancer
2007,
43
(2):291
-
298.

Ryden L, Chebil G, Sjostrom L, Pawlowski R, Jonsson PE:
Determination of sentinel lymph node (SLN)
status in primary breast
cancer by prospective use of immunohistochemistry increases the
rate of micrometastases and isolated tumour cells: analysis of 174 patients after SLN
biopsy
.
Eur J Surg Oncol
2007,
33
(1):33
-
38.

Schule J, Frisell J, Ingvar C, Bergkvist L:
Sentinel node biop
sy for breast cancer larger than 3 cm in
diameter
.
Br J Surg
2007,
94
(8):948
-
951.

Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M,
Mariani G, Baselga J

et al
:
2
-
year follow
-
up of trastuzumab after adjuvant chemo
therapy in
HER2
-
positive breast cancer: a randomised controlled trial
.
Lancet
2007,
369
(9555):29
-
36.

Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua
R, Bighin C, Klijn JG

et al
:
Trastuzumab
-
associated cardia
c adverse effects in the herceptin
adjuvant trial
.
J Clin Oncol
2007,
25
(25):3859
-
3865.

Villman K, Ohd JF, Lidbrink E, Malmberg L, Lindh B, Blomqvist C, Nordgren H, Bergh J, Bergstrom D,
Ahlgren J:
A phase II study of epirubicin, cisplatin and capecitabine

as neoadjuvant
chemotherapy in locally advanced or inflammatory breast cancer
.
Eur J Cancer
2007,
43
(7):1153
-
1160.

von Wachenfeldt A, Lindblom A, Gronberg H, Einbeigi Z, Rosenquist R, Gardman C, Iselius L:
A
hypothesis
-
generating search for new genetic br
east cancer syndromes
--
a national study in
803 Swedish families
.
Hered Cancer Clin Pract
2007,
5
(1):17
-
24.

Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmstrom P, Kellokumpu
-
Lehtinen P,
Bengtsson NO, Soderlund G, Anker G

et al
:
Long
-
term fol
low
-
up of the SBG 9401 study
comparing tailored FEC
-
based therapy versus marrow
-
supported high
-
dose therapy
.
Ann
Oncol
2007,
18
(4):694
-
700.


2006


Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, Ryden L, Gallagher WM,
O'Brien SL:
CA
IX is an independent prognostic marker in premenopausal breast cancer
patients with one to three positive lymph nodes and a putative marker of radiation
resistance
.
Clin Cancer Res
2006,
12
(21):6421
-
6431.

Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M,

Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P

et al
:
Validation and clinical utility of a 70
-
gene prognostic signature for women with node
-
negative breast cancer
.
J Natl Cancer Inst
2006,
98
(17):1183
-
1192.

Celebioglu F, Sylvan M, Perbeck L, Bergkv
ist L, Frisell J:
Intraoperative sentinel lymph node
examination by frozen section, immunohistochemistry and imprint cytology during breast
surgery
--
a prospective study
.
Eur J Cancer
2006,
42
(5):617
-
620.

Eaker S, Dickman PW, Bergkvist L, Holmberg L:
Differ
ences in management of older women
influence breast cancer survival: results from a population
-
based database in Sweden
.
PLoS
Med
2006,
3
(3):e25.

Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, Edlund P, Ewertz M, de Graaf
PW, Kamby C

et al
:
Similar efficacy for ovarian ablation compared with cyclophosphamide,
methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients
with node
-
positive, hormone receptor
-
positive breast cancer
.
J Clin Oncol
2006,
24
(31):4956
-
4962.

Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H,
Holmberg L, Wallgren A:
SweDCIS: Radiotherapy after sector resection for ductal carcinoma
in situ of the breast. Results of a randomised trial in a populati
on offered mammography
screening
.
Acta Oncol
2006,
45
(5):536
-
543.

Gianni L, Panzini I, Li S, Gelber RD, Collins J, Holmberg SB, Crivellari D, Castiglione
-
Gertsch M,
Goldhirsch A, Coates AS

et al
:
Ocular toxicity during adjuvant chemoendocrine therapy for
e
arly breast cancer: results from International Breast Cancer Study Group trials
.
Cancer
2006,
106
(3):505
-
513.

Kronblad A, Jirstrom K, Ryden L, Nordenskjold B, Landberg G:
Hypoxia inducible factor
-
1alpha is a
prognostic marker in premenopausal patients with

intermediate to highly differentiated
breast cancer but not a predictive marker for tamoxifen response
.
Int J Cancer
2006,
118
(10):2609
-
2616.

Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche
I

et
al
:
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast
cancer
.
Clin Cancer Res
2006,
12
(4):1157
-
1167.

Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E,
Pagani O

et al
:
Ident
ifying breast cancer patients at risk for Central Nervous System (CNS)
metastases in trials of the International Breast Cancer Study Group (IBCSG)
.
Ann Oncol
2006,
17
(6):935
-
944.

Ringberg A, Bageman E, Rose C, Ingvar C, Jernstrom H:
Of cup and bra size: re
ply to a prospective
study of breast size and premenopausal breast cancer incidence
.
Int J Cancer
2006,
119
(9):2242
-
2243; author reply 2244.

Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard
J, Price KN

et a
l
:
Randomized trial comparing axillary clearance versus no axillary clearance
in older patients with breast cancer: first results of International Breast Cancer Study
Group Trial 10
-
93
.
J Clin Oncol
2006,
24
(3):337
-
344.

Stendahl M, Ryden L, Nordenskjold B,

Jonsson PE, Landberg G, Jirstrom K:
High progesterone
receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal
breast cancer patients
.
Clin Cancer Res
2006,
12
(15):4614
-
4618.

Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds

J, Nordgren H, Farmer P, Praz V, Haibe
-
Kains B

et
al
:
Gene expression profiling in breast cancer: understanding the molecular basis of
histologic grade to improve prognosis
.
J Natl Cancer Inst
2006,
98
(4):262
-
272.

Tanner M, Isola J, Wiklund T, Erikstein B
, Kellokumpu
-
Lehtinen P, Malmstrom P, Wilking N, Nilsson J,
Bergh J:
Topoisomerase IIalpha gene amplification predicts favorable treatment response
to tailored and dose
-
escalated anthracycline
-
based adjuvant chemotherapy in HER
-
2/neu
-
amplified breast cance
r: Scandinavian Breast Group Trial 9401
.
J Clin Oncol
2006,
24
(16):2428
-
2436.


2005


Albain KS, de la Garza Salazar J, Pienkowski T, Aapro M, Bergh J, Caleffi M, Coleman R, Eiermann W,
Icli F, Pegram M

et al
:
Reducing the global breast cancer burden: the
importance of patterns
of care research
.
Clin Breast Cancer
2005,
6
(5):412
-
420.

Bergman A, Flodin A, Engwall Y, Arkblad EL, Berg K, Einbeigi Z, Martinsson T, Wahlstrom J, Karlsson P,
Nordling M:
A high frequency of germline BRCA1/2 mutations in western Swe
den detected
with complementary screening techniques
.
Fam Cancer
2005,
4
(2):89
-
96.

Bergkvist L, Frisell J:
Multicentre validation study of sentinel node biopsy for staging in breast
cancer
.
Br J Surg
2005,
92
(10):1221
-
1224.

Clarke M, Collins R, Darby S, Da
vies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S

et al
:
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer
on local recurrence and 15
-
year survival: an overview of the randomised trials
.
Lancet
200
5,
366
(9503):2087
-
2106.

Colleoni M, Li S, Gelber RD, Coates AS, Castiglione
-
Gertsch M, Price KN, Lindtner J, Rudenstam CM,
Crivellari D, Collins J

et al
:
Timing of CMF chemotherapy in combination with tamoxifen in
postmenopausal women with breast cancer: r
ole of endocrine responsiveness of the
tumor
.
Ann Oncol
2005,
16
(5):716
-
725.

Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam CM, Lindtner J, Erzen D,
Snyder R, Collins J

et al
:
Site of primary tumor has a prognostic role in operable b
reast
cancer: the international breast cancer study group experience
.
J Clin Oncol
2005,
23
(7):1390
-
1400.

Eaker S, Dickman PW, Hellstrom V, Zack MM, Ahlgren J, Holmberg L:
Regional differences in breast
cancer survival despite common guidelines
.
Cancer Epidemiol Biomarkers Prev
2005,
14
(12):2914
-
2918.

(EBCTCG) EBCTCG:
Effects of chemotherapy and hormonal therapy for early breast cancer on
recurrence and 15
-
year survival: an overview of the randomised trials
.
Lancet
2005,
365
(9472):1687
-
1717.

Grube
r G, Bonetti M, Nasi ML, Price KN, Castiglione
-
Gertsch M, Rudenstam CM, Holmberg SB,
Lindtner J, Golouh R, Collins J

et al
:
Prognostic value of extracapsular tumor spread for
locoregional control in premenopausal patients with node
-
positive breast cancer t
reated
with classical cyclophosphamide, methotrexate, and fluorouracil: long
-
term observations
from International Breast Cancer Study Group Trial VI
.
J Clin Oncol
2005,
23
(28):7089
-
7097.

Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adam
i HO, Hall P:
Genetic
implications of bilateral breast cancer: a population based cohort study
.
Lancet Oncol
2005,
6
(6):377
-
382.

Holmberg SB:
[Anti
-
hormone breast cancer treatment. Convincing trials do exist
--
we have to take
up a stand now!]
.
Lakartidninge
n
2005,
102
(41):2920
-
2921.

Jernstrom H, Loman N, Johannsson OT, Borg A, Olsson H:
Impact of teenage oral contraceptive use
in a population
-
based series of early
-
onset breast cancer cases who have undergone BRCA
mutation testing
.
Eur J Cancer
2005,
41
(15):2
312
-
2320.

Jirstrom K, Ryden L, Anagnostaki L, Nordenskjold B, Stal O, Thorstenson S, Chebil G, Jonsson PE,
Ferno M, Landberg G:
Pathology parameters and adjuvant tamoxifen response in a
randomised premenopausal breast cancer trial
.
J Clin Pathol
2005,
58
(1
1):1135
-
1142.

Jirstrom K, Stendahl M, Ryden L, Kronblad A, Bendahl PO, Stal O, Landberg G:
Adverse effect of
adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification
.
Cancer Res
2005,
65
(17):8009
-
8016.

Kald BA, Boiesen P, Ronnow
K, Jonsson PE, Bisgaard T:
Preoperative assessment of small tumours in
women with breast cancer
.
Scand J Surg
2005,
94
(1):15
-
20.

Nordenskjold B, Rosell J, Rutqvist LE, Malmstrom PO, Bergh J, Bengtsson NO, Hatschek T, Wallgren A,
Carstensen J:
Coronary
heart disease mortality after 5 years of adjuvant tamoxifen therapy:
results from a randomized trial
.
J Natl Cancer Inst
2005,
97
(21):1609
-
1610.

Poikonen P, Sjostrom J, Amini RM, Villman K, Ahlgren J, Blomqvist C:
Cyclin A as a marker for
prognosis and che
motherapy response in advanced breast cancer
.
Br J Cancer
2005,
93
(5):515
-
519.

Ryden L, Jirstrom K, Bendahl PO, Ferno M, Nordenskjold B, Stal O, Thorstenson S, Jonsson PE,
Landberg G:
Tumor
-
specific expression of vascular endothelial growth factor receptor

2 but
not vascular endothelial growth factor or human epidermal growth factor receptor 2 is
associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer
.
J Clin Oncol
2005,
23
(21):4695
-
4704.

Ryden L, Jonsson PE, Chebil G, Dufmats

M, Ferno M, Jirstrom K, Kallstrom AC, Landberg G, Stal O,
Thorstenson S

et al
:
Two years of adjuvant tamoxifen in premenopausal patients with
breast cancer: a randomised, controlled trial with long
-
term follow
-
up
.
Eur J Cancer
2005,
41
(2):256
-
264.


2004


Batista N, Perez
-
Manga G, Constenla M, Ruiz A, Carabantes F, Castellanos J, Gonzalez Baron M,
Villman K, Soderberg M, Ahlgren J

et al
:
Phase II study of capecitabine in combination with
paclitaxel in patients with anthracycline
-
pretreated advanced/metastat
ic breast cancer
.
Br
J Cancer
2004,
90
(9):1740
-
1746.

Berclaz G, Li S, Price KN, Coates AS, Castiglione
-
Gertsch M, Rudenstam CM, Holmberg SB, Lindtner J,
Erien D, Collins J

et al
:
Body mass index as a prognostic feature in operable breast cancer:
the Intern
ational Breast Cancer Study Group experience
.
Ann Oncol
2004,
15
(6):875
-
884.

Bergkvist L, Liljegren G, Ahlgren J, Lidin A, Holmqvist M, Holmberg L:
[Registries contribute to better
breast cancer care]
.
Lakartidningen
2004,
101
(34):2579
-
2581.

Dalberg K, Johansson H, Signomklao T, Rutqvist LE, Bergkvist L, Frisell J, Liljegren G, Ambre T, Sandelin
K:
A randomised study of axillary drainage and pectoral fascia preservation after
mastectomy for breast cancer
.
Eur J Surg Oncol
2004,
30
(6):602
-
609.

Holmberg L, Anderson H:
HABITS (hormonal replacement therapy after breast cancer
--
is it safe?), a
randomised comparison: trial stopped
.
Lancet
2004,
363
(9407):453
-
455.

Lindahl T, Landberg G, Ahlgren J, Nordgren H, Norberg T, Klaar S, Holmberg L, Bergh J:
O
verexpression of cyclin E protein is associated with specific mutation types in the p53
gene and poor survival in human breast cancer
.
Carcinogenesis
2004,
25
(3):375
-
380.

Lindqvist R, Alvegard TA, Jonsson PE, Stenbeck M:
Hospital stay related to TNM
-
stage
and the
surgical procedure in primary breast cancer
.
Acta Oncol
2004,
43
(6):545
-
550.

Malander S, Ridderheim M, Masback A, Loman N, Kristoffersson U, Olsson H, Nilbert M, Borg A:
One
in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: re
sults of a
prospective study in Southern Sweden
.
Eur J Cancer
2004,
40
(3):422
-
428.

Nilsson
-
Ihrfelt E, Fjallskog ML, Blomqvist C, Ahlgren J, Edlund P, Hansen J, Malmberg L, Villman K,
Andersson G:
Breast cancer on the Internet: the quality of Swedish breast

cancer websites
.
Breast
2004,
13
(5):376
-
382.

Ryden L, Boiesen P, Jonsson PE:
Assessment of microvessel density in core needle biopsy specimen
in breast cancer
.
Anticancer Res
2004,
24
(1):371
-
375.

Ryden L, Linderholm B, Nielsen NH, Emdin S, Jonsson PE, Lan
dberg G:
Tumor specific VEGF
-
A and
VEGFR2/KDR protein are co
-
expressed in breast cancer
.
Breast Cancer Res Treat
2004,
82
(3):147
-
154.

Schule JM, Bergkvist L, Hakansson L, Gustafsson B, Hakansson A:
CD28 expression in sentinel node
biopsies from breast
cancer patients in comparison with CD3
-
zeta chain expression
.
J Transl
Med
2004,
2
(1):45.


2003


Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O,
Borg A

et al
:
Average risks of breast and ovarian cancer ass
ociated with BRCA1 or BRCA2
mutations detected in case Series unselected for family history: a combined analysis of 22
studies
.
Am J Hum Genet
2003,
72
(5):1117
-
1130.

Baldetorp B, Bendahl PO, Ferno M, Stal O:
Improved DNA flow cytometric, DNA ploidy, and S
-
phase
reproducibility between 15 laboratories in analysis of breast cancer using generalized
guidelines
.
Cytometry A
2003,
56
(1):1
-
7.

Brandberg Y, Michelson H, Nilsson B, Bolund C, Erikstein B, Hietanen P, Kaasa S, Nilsson J, Wiklund T,
Wilking N

et al
:
Qu
ality of life in women with breast cancer during the first year after
random assignment to adjuvant treatment with marrow
-
supported high
-
dose
chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with
Fluorouracil, epirubicin, a
nd cyclophosphamide: Scandinavian Breast Group Study 9401
.
J
Clin Oncol
2003,
21
(19):3659
-
3664.

Chebil G, Bendahl PO, Ferno M:
Estrogen and progesterone receptor assay in paraffin
-
embedded
breast cancer
--
reproducibility of assessment
.
Acta Oncol
2003,
42
(1):43
-
47.

Chebil G, Bendahl PO, Idvall I, Ferno M:
Comparison of immunohistochemical and biochemical assay
of steroid receptors in primary breast cancer
--
clinical associations and reasons for
discrepancies
.
Acta Oncol
2003,
42
(7):719
-
725.

Fredriksson I, L
iljegren G, Palm
-
Sjovall M, Arnesson LG, Emdin SO, Fornander T, Lindgren A, Nordgren
H, Idvall I, Holmqvist M

et al
:
Risk factors for local recurrence after breast
-
conserving
surgery
.
Br J Surg
2003,
90
(9):1093
-
1102.

Loman N, Bladstrom A, Johannsson O, Bor
g A, Olsson H:
Cancer incidence in relatives of a
population
-
based set of cases of early
-
onset breast cancer with a known BRCA1 and BRCA2
mutation status
.
Breast Cancer Res
2003,
5
(6):R175
-
186.

Luoma ML, Hakamies
-
Blomqvist L, Sjostrom J, Pluzanska A, Ottos
on S, Mouridsen H, Bengtsson NO,
Bergh J, Malmstrom P, Valvere V

et al
:
Prognostic value of quality of life scores for time to
progression (TTP) and overall survival time (OS) in advanced breast cancer
.
Eur J Cancer
2003,
39
(10):1370
-
1376.

Malmstrom P, Hol
mberg L, Anderson H, Mattsson J, Jonsson PE, Tennvall
-
Nittby L, Balldin G, Loven L,
Svensson JH, Ingvar C

et al
:
Breast conservation surgery, with and without radiotherapy, in
women with lymph node
-
negative breast cancer: a randomised clinical trial in a p
opulation
with access to public mammography screening
.
Eur J Cancer
2003,
39
(12):1690
-
1697.

Ryden L, Boiesen P, Jonsson PE:
Decreased angiogenic activity in breast cancer in ever
-
users of oral
contraceptive therapy
--
preliminary report
.
Anticancer Res
2003,

23
(3C):2875
-
2878.

Wallgren A, Bonetti M, Gelber RD, Goldhirsch A, Castiglione
-
Gertsch M, Holmberg SB, Lindtner J,
Thurlimann B, Fey M, Werner ID

et al
:
Risk factors for locoregional recurrence among breast
cancer patients: results from International Breas
t Cancer Study Group Trials I through VII
.
J
Clin Oncol
2003,
21
(7):1205
-
1213.

Wilczek B, Aspelin P, Bone B, Pegerfalk A, Frisell J, Danielsson R:
Complementary use of
scintimammography with 99m
-
Tc
-
MIBI to triple diagnostic procedure in palpable and
non
-
palpable breast lesions
.
Acta Radiol
2003,
44
(3):288
-
293.


2002


Ahlgren J, Holmberg L, Bergh J, Liljegren G:
Five
-
node biopsy of the axilla: an alternative to axillary
dissection of levels I
-
II in operable breast cancer
.
Eur J Surg Oncol
2002,
28
(2):9
7
-
102.

Andersson J, Linderholm B, Greim G, Lindh B, Lindman H, Tennvall J, Tennvall
-
Nittby L, Pettersson
-
Skold D, Sverrisdottir A, Soderberg M

et al
:
A population
-
based study on the first forty
-
eight
breast cancer patients receiving trastuzumab (Herceptin)

on a named patient basis in
Sweden
.
Acta Oncol
2002,
41
(3):276
-
281.

CollaborativeGrouponHormonalFactorsinBreastCancer:
Breast cancer and breastfeeding:
collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries,
including
50302 women with breast cancer and 96973 women without the disease
.
Lancet
2002,
360
(9328):187
-
195.

Colleoni M, Litman HJ, Castiglione
-
Gertsch M, Sauerbrei W, Gelber RD, Bonetti M, Coates AS,
Schumacher M, Bastert G, Rudenstam CM

et al
:
Duration of adjuvan
t chemotherapy for
breast cancer: a joint analysis of two randomised trials investigating three versus six
courses of CMF
.
Br J Cancer
2002,
86
(11):1705
-
1714.

Einbeigi Z, Meis
-
Kindblom JM, Kindblom LG, Wallgren A, Karlsson P:
Clustering of individuals with

both breast and ovarian cancer
--
a possible indicator of BRCA founder mutations
.
Acta
Oncol
2002,
41
(2):153
-
157.

Fredriksson I, Liljegren G, Arnesson LG, Emdin SO, Palm
-
Sjovall M, Fornander T, Holmqvist M,
Holmberg L, Frisell J:
Consequences of axillary re
currence after conservative breast surgery
.
Br J Surg
2002,
89
(7):902
-
908.

Fredriksson I, Liljegren G, Arnesson LG, Emdin SO, Palm
-
Sjovall M, Fornander T, Holmqvist M,
Holmberg L, Frisell J:
Local recurrence in the breast after conservative surgery
--
a
study of
prognosis and prognostic factors in 391 women
.
Eur J Cancer
2002,
38
(14):1860
-
1870.

Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, Jr., Coates RJ, Liff JM, Talamini R,
Chantarakul N

et al
:
Alcohol, tobacco and breast cancer
--
collabor
ative reanalysis of
individual data from 53 epidemiological studies, including 58,515 women with breast
cancer and 95,067 women without the disease
.
Br J Cancer
2002,
87
(11):1234
-
1245.

Hernberg M, Virkkunen P, Maasilta P, Keyrilainen J, Blomqvist C, Bergh J, Wiklund T:
Pulmonary
toxicity after radiotherapy in primary breast cancer patients: results from a randomized
chemotherapy study
.
Int J Radiat Oncol Biol Phys
2002,
52
(1):128
-
136.

Ny
strom L, Andersson I, Bjurstam N, Frisell J, Nordenskjold B, Rutqvist LE:
Long
-
term effects of
mammography screening: updated overview of the Swedish randomised trials
.
Lancet
2002,
359
(9310):909
-
919.

Ryden L, Chebil G, Jonsson PE:
Small bowel obstruction
caused by intestinal metastases from
undiagnosed breast cancer: report of two cases
.
Eur J Surg
2002,
168
(11):648
-
650.

Schule J, Bergkvist L, Hakansson L, Gustafsson B, Hakansson A:
Down
-
regulation of the CD3
-
zeta
chain in sentinel node biopsies from breas
t cancer patients
.
Breast Cancer Res Treat
2002,
74
(1):33
-
40.

Sjostrom J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Malmstrom P,
Ostenstad B, Wist E, Valvere V

et al
:
C
-
erbB
-
2 expression does not predict response to
docetaxel or s
equential methotrexate and 5
-
fluorouracil in advanced breast cancer
.
Eur J
Cancer
2002,
38
(4):535
-
542.


2001


Bergh J, Holmquist M:
Who should not receive adjuvant chemotherapy? International databases
.
J
Natl Cancer Inst Monogr
2001(30):103
-
108.

Bergh J, Jonsson PE, Glimelius B, Nygren P:
A systematic overview of chemotherapy effects in breast
cancer
.
Acta Oncol
2001,
40
(2
-
3):253
-
281.

Bergkvist L, Frisell J, Liljegren G, Celebioglu F, Damm S, Thorn M:
Multicentre study of detection and
false
-
negat
ive rates in sentinel node biopsy for breast cancer
.
Br J Surg
2001,
88
(12):1644
-
1648.

Bergman A, Einbeigi Z, Olofsson U, Taib Z, Wallgren A, Karlsson P, Wahlstrom J, Martinsson T,
Nordling M:
The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM c
onserved
haplotype of today is a reminiscence of a 1500
-
year
-
old mutation
.
Eur J Hum Genet
2001,
9
(10):787
-
793.

Colleoni M, Gelber S, Coates AS, Castiglione
-
Gertsch M, Gelber RD, Price K, Rudenstam CM, Lindtner
J, Collins J, Thurlimann B

et al
:
Influence o
f endocrine
-
related factors on response to
perioperative chemotherapy for patients with node
-
negative breast cancer
.
J Clin Oncol
2001,
19
(21):4141
-
4149.

Einbeigi Z, Bergman A, Kindblom LG, Martinsson T, Meis
-
Kindblom JM, Nordling M, Suurkula M,
Wahlstrom
J, Wallgren A, Karlsson P:
A founder mutation of the BRCA1 gene in Western
Sweden associated with a high incidence of breast and ovarian cancer
.
Eur J Cancer
2001,
37
(15):1904
-
1909.

Fredriksson I, Liljegren G, Arnesson LG, Emdin SO, Palm
-
Sjovall M, Fornand
er T, Frisell J, Holmberg L:
Time trends in the results of breast conservation in 4694 women
.
Eur J Cancer
2001,
37
(12):1537
-
1544.

Frisell J, Bergqvist L, Liljegren G, Thorn M, Damm S, Rydman H, Danielsson R:
Sentinel node in breast
cancer
--
a Swedish pilot

study of 75 patients
.
Eur J Surg
2001,
167
(3):179
-
183.

Glimelius B, Bergh J, Brandt L, Brorsson B, Gunnars B, Hafstrom L, Haglund U, Hogberg T, Janunger
KG, Jonsson PE

et al
:
The Swedish Council on Technology Assessment in Health Care (SBU)
systematic
overview of chemotherapy effects in some major tumour types
--
summary and
conclusions
.
Acta Oncol
2001,
40
(2
-
3):135
-
154.

Hakamies
-
Blomqvist L, Luoma ML, Sjostrom J, Pluzanska A, Sjodin M, Mouridsen H, Ostenstad B,
Mjaaland I, Ottosson S, Bergh J

et al
:
Timi
ng of quality of life (QoL) assessments as a source
of error in oncological trials
.
J Adv Nurs
2001,
35
(5):709
-
716.

Hall KS, Wiklund T, Erikstein B, Holte H, Kvalheim G, Sommer HH, Andersen A, Skovlund E, Bergh J,
Hall C:
Effects of dose
-
intensive chemothe
rapy and radiotherapy on serum n
-
terminal
proatrial natriuretic peptide in high
-
risk breast cancer patients
.
Breast Cancer Res Treat
2001,
67
(3):235
-
244.

Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller
M, Ka
llioniemi OP

et al
:
Gene
-
expression profiles in hereditary breast cancer
.
N Engl J Med
2001,
344
(8):539
-
548.

Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J:
The expression
of vascular endothelial growth factor correlat
es with mutant p53 and poor prognosis in
human breast cancer
.
Cancer Res
2001,
61
(5):2256
-
2260.

Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A:
Family history of breast and ovarian
cancers and BRCA1 and BRCA2 mutations in a population
-
based seri
es of early
-
onset breast
cancer
.
J Natl Cancer Inst
2001,
93
(16):1215
-
1223.

Malmstrom P, Bendahl PO, Boiesen P, Brunner N, Idvall I, Ferno M:
S
-
phase fraction and urokinase
plasminogen activator are better markers for distant recurrences than Nottingham
Pr
ognostic Index and histologic grade in a prospective study of premenopausal lymph
node
-
negative breast cancer
.
J Clin Oncol
2001,
19
(7):2010
-
2019.

Vallon
-
Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brondum
-
Nielsen K,
Gerdes AM, Molle
r P, Kristoffersson U, Olsson H

et al
:
Functional analysis of BRCA1 C
-
terminal missense mutations identified in breast and ovarian cancer families
.
Hum Mol
Genet
2001,
10
(4):353
-
360.

Warnberg F, Bergh J, Zack M, Holmberg L:
Risk factors for subsequent
invasive breast cancer and
breast cancer death after ductal carcinoma in situ: a population
-
based case
-
control study
in Sweden
.
Cancer Epidemiol Biomarkers Prev
2001,
10
(5):495
-
499.


2000


Arnesson LG, Ahlgren J:
Omitting axillary surgery for low
-
risk
breast cancer patients
--
a Swedish
prospective cohort study
.
Acta Oncol
2000,
39
(3):291
-
294.

Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu
-
Lehtinen P,
Bengtsson NO, Soderlund G, Anker G

et al
:
Tailored fluorouracil, epirubi
cin, and
cyclophosphamide compared with marrow
-
supported high
-
dose chemotherapy as
adjuvant treatment for high
-
risk breast cancer: a randomised trial. Scandinavian Breast
Group 9401 study
.
Lancet
2000,
356
(9239):1384
-
1391.

Boiesen P, Bendahl PO, Anagnostak
i L, Domanski H, Holm E, Idvall I, Johansson S, Ljungberg O,
Ringberg A, Ostberg G

et al
:
Histologic grading in breast cancer
--
reproducibility between
seven pathologic departments. South Sweden Breast Cancer Group
.
Acta Oncol
2000,
39
(1):41
-
45.

Colleoni M,

Bonetti M, Coates AS, Castiglione
-
Gertsch M, Gelber RD, Price K, Rudenstam CM,
Lindtner J, Collins J, Thurlimann B

et al
:
Early start of adjuvant chemotherapy may improve
treatment outcome for premenopausal breast cancer patients with tumors not expressin
g
estrogen receptors. The International Breast Cancer Study Group
.
J Clin Oncol
2000,
18
(3):584
-
590.

Erselcan T, Kairemo KJ, Wiklund TA, Hernberg M, Blomqvist CP, Tenhunen M, Bergh J, Joensuu H:
Subclinical cardiotoxicity following adjuvant dose
-
escalated
FEC, high
-
dose chemotherapy,
or CMF in breast cancer
.
Br J Cancer
2000,
82
(4):777
-
781.

Ferno M, Stal O, Baldetorp B, Hatschek T, Kallstrom AC, Malmstrom P, Nordenskjold B, Ryden S:
Results of two or five years of adjuvant tamoxifen correlated to steroid re
ceptor and S
-
phase levels. South Sweden Breast Cancer Group, and South
-
East Sweden Breast Cancer
Group
.
Breast Cancer Res Treat
2000,
59
(1):69
-
76.

Larsson PA, Glimelius B, Jeppsson B, Jonsson PE, Malmberg M, Gustavsson B, Carlsson G, Svedberg
M:
A
pharmacokinetic study of 5
-
FU/leucovorin and alpha
-
interferon in advanced cancer
.
Acta Oncol
2000,
39
(1):59
-
63.

Loman N, Johannsson O, Bendahl P, Dahl N, Einbeigi Z, Gerdes A, Borg A, Olsson H:
Prognosis and
clinical presentation of BRCA2
-
associated breast

cancer
.
Eur J Cancer
2000,
36
(11):1365
-
1373.

Ringberg A, Idvall I, Ferno M, Anderson H, Anagnostaki L, Boiesen P, Bondesson L, Holm E, Johansson
S, Lindholm K

et al
:
Ipsilateral local recurrence in relation to therapy and morphological
characteristics in
patients with ductal carcinoma in situ of the breast
.
Eur J Surg Oncol
2000,
26
(5):444
-
451.

Sjostrom J, Blomqvist C, Heikkila P, Boguslawski KV, Raisanen
-
Sokolowski A, Bengtsson NO, Mjaaland
I, Malmstrom P, Ostenstadt B, Bergh J

et al
:
Predictive value of
p53, mdm
-
2, p21, and mib
-
1
for chemotherapy response in advanced breast cancer
.
Clin Cancer Res
2000,
6
(8):3103
-
3110.

Stal O, Borg A, Ferno M, Kallstrom AC, Malmstrom P, Nordenskjold B:
ErbB2 status and the benefit
from two or five years of adjuvant tamoxi
fen in postmenopausal early stage breast cancer
.
Ann Oncol
2000,
11
(12):1545
-
1550.